Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Catherine Williams(University College Hospital), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Sarah Brown(University of Leeds), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Samantha Hinsley(University of Leeds), Eric Low(Myeloma UK), Neil Rabin(University College London), Jamie Cavenagh(St Bartholomew's Hospital), Louise Flanagan(University of Leeds)
Cited by 6
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605